

Amendments to the claims:

1-64 (cancelled)

65. (previously presented) A pharmaceutical composition comprising a monovalent antibody fragment which binds *in vivo* to human platelet glycoprotein GPIb without incurring thrombocytopenia and a pharmaceutically acceptable carrier.

66. (previously presented) The pharmaceutical composition according to claim 65, wherein said fragment is a Fab fragment or a single variable domain.

67. (cancelled)

68. (cancelled)

69. (cancelled)

70. (previously presented) The pharmaceutical composition according to claim 65, wherein the variable region of said fragment comprises SEQ ID NO: 4.

71. (previously presented) The pharmaceutical composition according to claim 65,

wherein said monovalent antibody fragment is obtained from a monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.

72. (cancelled)

73. (cancelled)

74. (cancelled)

75. (cancelled)

76. (cancelled)

77. (cancelled)

78. (cancelled)

79. (cancelled)

80. (previously presented) A monoclonal antibody produced by the cell line deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.
81. (previously presented) A cell line, capable of producing an antibody directed against GP1b deposited with the Belgian Coordinated Collections of Microorganisms, under accession number LMBP 5108CB.
82. (previously presented) A humanized antibody fragment derivable from the monoclonal antibody of claim 80, wherein said humanized antibody fragment binds GP1b.
83. (cancelled)